
    
      Women age â‰¥ 18 years with triple-negative unresectable locally advanced or MBC that is not
      amenable to resection with curative intent.

      Patients must have received at least one, but not more than two, prior chemotherapeutic
      regimens for treatment of unresectable locally advanced and/or metastatic disease (at least
      one regimen must have contained a taxane).

      The number of patients to be included is 54 patients. The primary objective is to evaluate
      the safety and tolerability of ipatasertib (GDC-0068) in combination with capecitabine,
      eribulin, or carboplatin plus gemcitabine in patients with unresectable locally advanced or
      metastatic triple-negative breast cancer
    
  